Survey Results: What Traits do Businesses Look for in New Hires?

Express Employment Professionals released new survey results today revealing traits that are most important to businesses when hiring job candidates.

In a survey of 1,030 businesses, respondents were asked to, “Rate the following traits in order of importance when hiring a candidate with 1 being least important and 5 being most important.”

“Work ethic/integrity” topped the list, with an average rating of 4.60, followed closely by “attitude” at 4.57.

“Communication” was the only other trait with an average rating greater than 4. “Culture fit,” “critical thinking” and “consistent work history” followed, with “job experience,” “education” and “references” rounding out the bottom three.

“All of these traits matter; there’s no doubt about that,” said Bob Funk, CEO of Express, and a former chairman of the Federal Reserve Bank of Kansas City. “Still, you can help someone build experience or knowledge, but you can’t teach integrity or attitude. That’s reflected in this survey, and it is why employers put such a premium on these traits. Communication and cultural fit are very similar in that regard as well. You just cannot afford to have someone on a team who’s going to harm others’ ability to get the job done.”

The survey of 1,030 businesses, which are current and former clients of Express Employment Professionals, was conducted in March 2017 to gauge respondents’ expectations for the second quarter of 2017. Previous surveys were conducted to cover job insights of the quarters indicated.

If you would like to arrange for an interview with Bob Funk to discuss this topic, please contact Sheena Karami, Director of Corporate Communications and PR, at (405) 717-5966.

About Robert A. Funk
Robert A. “Bob” Funk is chairman and chief executive officer of Express Employment Professionals. Headquartered in Oklahoma City, the international staffing company has more than 770 franchises in the U.S., Canada and South Africa. Under his leadership, Express has put more than 6 million people to work worldwide. Funk served as Chairman of the Conference of Chairmen of the Federal Reserve and was also the Chairman of the Federal Reserve Bank of Kansas City.

About Express Employment Professionals
Express Employment Professionals puts people to work. It generated $3.05 billion in sales and employed a record 510,000 people in 2016. Its long-term goal is to put a million people to work annually. For more information, visit

Share article on social media or email:

Plandai Biotechnology, Inc. (PLPL: OTC Pink Limited) | Plandai Biotechnology Gains Credibility with NutriBullet Deal

NEW YORK, NY–(Marketwired – April 26, 2017) – Plandaí Biotechnology (OTCQB: PLPL) expects Capital Brands, LLC, the developer, marketer, and distributor of both the wildly popular NutriBullet and NutriBullet SuperFoods, to launch its reformulated product, SuperFood Fat Burning Boost®, next month. SuperFood Fat Burning Boost® is being reformulated to include Plandaí’s Phytofare® Catechin Complex. This is a landmark moment for a company like Plandaí Biotechnology that has just recently moved from solely a research and development company to focusing more on sales and marketing of its Phytofare® product.

More than 40 million NutriBullet units have been sold worldwide, it’s an Amazon best seller in a number of categories and even Kate Middleton, the Duchess of Cambridge and the wife of Prince William, is a big fan of NutriBullet. Capital Brands produces SuperFood formula mixes that it says is to help „give the consumer the best possible health benefits using only the best and most quality ingredients available.” The company focuses on nutrient extraction in order to deliver the most nutrients possible from food and other ingredients to increase the health of people everywhere.

Capital Brands has chosen Plandaí Biotechnology’s Phytofare® as one of those quality ingredients it will deliver, and now some time next month Phytofare® is expected to be introduced to Capital Brands’ retailers (Target, Kohl’s, Best Buy, Bed Bath & Beyond, Walmart, JC Penny, etc.) and to shoppers who use their website ( as the active ingredient in SuperFood Fat Burning Boost®. This is a deal that should immediately give Plandaí credibility. After all, Plandaí invested many years of hard work into the development of Phytofare®, and having a worldwide brand that is well-known for using „only the best and most quality ingredients” in its products, speaks loudly to just how potent Phytofare® is.

Capital Brands reformulating one of its SuperFood products to include Plandaí’s Phytofare®, should also serve as confirmation for the many years of research and the human clinical trials that Plandaí conducted to prove that its product is highly bioavailable. Bioavailability is essentially the measure of how much of a drug or supplement is able to be absorbed into the bloodstream and how long it can remain there so that the body can realize its health benefits. In the case of Plandaí’s Phytofare® Catechin Complex, Capital Brands obviously feels that the results will offer exactly what its customers want.

A human clinical trial showed Plandaí’s product offers 10 times more bioavailability than the commercially available extract it was compared to, and the results from the clinical trial, which was conducted in South Africa by North West University, have allowed Plandaí to advertise exactly what consumers are looking for — a more potent green tea extract.

Green tea’s health benefits come from the 8 catechins, a type of antioxidant, found in the leaves of the tea plant. In Plandaí’s clinical trial, all 8 of those catechins were present in the bloodstream versus only two found when participants consumed the commercial extract that was used in the clinical testing. Phytofare® also provided 5 times greater absorption of those catechins, and the clinical trial found that the life span of the catechin’s molecules in the bloodstream was doubled in Phytofare®.

When consumers shop for health products, they’re looking for those that have proven themselves in clinical trials, and, in turn, can boast of higher bioavailability. Capital Brands has created a worldwide brand with that thinking in mind, and it’s no mistake that the company has landed at Plandaí’s door.

The benefit to those using the Plandaí’s Phytofare® Catechin Complex is that with higher bioavailability or absorption rate, the phytonutrients are in the bloodstream in greater quantities and for twice as long, and now as the company has become fully focused on sales and marketing, the credibility of this NutriBullet deal along with powerful clinical trial results, should help the company become extremely competitive in the market.

About Stock Market Media Group
Stock Market Media Group is a Content Development IR firm offering a platform for corporate stories to unfold in the media with research reports, corporate videos, CEO interviews and feature news articles.

We may from time to time include our own opinions about our featured companies, their businesses, markets and opportunities. Any opinions we may offer are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers and viewers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice, or construed or interpreted as research. Any investment decisions you may make concerning any company are solely your responsibility based on your own due diligence. Our publications are provided only as an informational aid. We encourage you to invest carefully and read the investor information available at the web site of the U.S. Securities and Exchange Commission at: We also recommend as a general rule, that before investing in any securities you consult with a professional financial planner or advisor, and you should conduct a complete and independent investigation before investing in any security after prudent consideration of all pertinent risks.

We are not a registered broker, dealer, analyst, or adviser. We hold no investment licenses and may not sell, offer to sell or offer to buy any security. Our publications are not a recommendation to buy or sell a security.

Section 17(b) of the 1933 Securities and Exchange Act requires publishers who distribute information about publicly traded securities for compensation, to disclose who paid them, the amount, and the type of payment. In order to be in full compliance with the Securities Act of 1933, Section 17(b), we are disclosing that SMMG is compensated $5,000 per month by Plandai Biotechnology for content development. Neither SMMG nor anyone associated with it owns shares in PLPL.

For more information:

Copyright © 2017 Marketwired. All Rights Reserved

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

Titan Medical Inc. (TITXF: OTCQX International) | Titan Medical Issued U.S. Patent Related to SPORT Surgical System Robotic Instruments

TORONTO, ON–(Marketwired – April 26, 2017) – Titan Medical Inc. (TSX: TMD) (OTCQX: TITXF), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (MIS), announces the issuance of U.S. Patent No. 9,629,688 titled „Actuator and Drive for Manipulating a Tool,” which covers the Company’s unique robotic surgical instruments and in particular the novel interface and drive mechanism.

The patent generally describes a tool apparatus that includes actuators mounted in a housing in such a way to facilitate travel in a substantially orthogonal direction to the actuating direction of control links, which drive movement of the tool apparatus.

„This issuance of this patent is extremely important to Titan Medical and our development of the SPORT single port robotic surgery system, as it protects our system from would-be competitors and distinguishes our system from existing robotic technologies,” said David McNally, the company’s Chief Executive Officer. „In addition to the novelty of the instrument design, this patent covers key characteristics we believe will be beneficial for commercial adoption. For example, the technology was developed to provide ease of instrument loading, and it facilitates close instrument proximity when loaded in a surgical system. This is especially important for minimizing the insertion mechanism diameter and ultimately, the incision size in single-port surgery. In addition, the interface design allows for reduced tension on the instrument cables, which potentially extends the life of the reusable device.”

The Company expects to file select foreign patent applications related to the issued patent, in addition to a related U.S. continuation application that has previously been filed.

About Titan Medical Inc.

Titan Medical Inc. is focused on the design and development through the planned commercialization of a robotic surgical system for use in MIS. The Company’s SPORT Surgical System, currently under development, includes a surgeon-controlled robotic platform that features multi-articulating instruments for performing MIS procedures through a single incision. The surgical system also includes a workstation that provides a surgeon with an advanced ergonomic interface to the robotic platform for controlling the instruments and provides a 3D high-definition endoscopic view inside a patient’s body. The SPORT Surgical System is designed to enable surgeons to perform a broad set of general abdominal, gynecologic and urologic procedures. For more information, visit the Company’s website at

Forward-Looking Statements

This news release contains „forward-looking statements” which reflect the current expectations of management of the Company’s future growth, results of operations, performance and business prospects and opportunities. Wherever possible, words such as „may”, „would”, „could”, „will”, „anticipate”, „believe”, „plan”, „expect”, „intend”, „estimate”, „potential for” and similar expressions have been used to identify these forward-looking statements. These statements reflect management’s current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, without limitation, those listed in the „Risk Factors” section of the Company’s Annual Information Form dated March 31, 2017 (which may be viewed at Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements.

Copyright © 2017 Marketwired. All Rights Reserved

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

Light Sensor Market Facts, Figures and Analytical Insights 2017 – 2027

Valley Cottage, NY — (SBWIRE) — 04/26/2017 — Manufacturers of consumer electronic devices such as smartphones and tablets are working on optimize energy consumption of these devices which is why manufacturers introduced light sensor technology. Light sensor devices are witnessing an increase in application in electronics devices such as mobiles, LCD and LED’s, which performs the function of automatically adjusting the screen brightness in response to the amount of the light these devices receives and helps in power saving for these devices.

Light Sensor Market: Market Dynamics

The factors driving the light sensors market include the growing implementation of light sensor functions in the consumer electronics such as smartphones and tablets. Also, advancements in the automotive sector, smart homes, and outdoor lighting are expected to boost the growth of the light sensors market.

Light sensors are expected to witness an increase in demand supported by growing implementation in sectors such as consumer electronics, automotive, building automation etc. Demand for light sensor devices is directly proportional to the region’s population and demand for consumer electronics, automobiles, that is why Asia-Pacific region is expected to dominate the market of light sensors.

Request For Report Sample:

Light Sensor Market Segmentation

Segmentation of Light Sensor Market on the basis of application:

Consumer Electronics
Industrial Manufacturing
Building Automation

Sub-Segmentation of Light Sensor Market on the basis of output:


Sub-Segmentation of Light Sensor Market on the basis of technology:

Radio wave
Radio Frequency

Segmentation of Light Sensor Market on the basis of geography:

North America (U.S., Canada)
Latin America (Mexico, Brazil)
Western Europe (Germany, Italy, France, U.K, Spain, Nordic countries, Belgium, Netherlands, Luxembourg)
Eastern Europe (Poland, Russia)
Asia-Pacific (China, India, ASEAN, Australia & New Zealand)
The Middle East and Africa (GCC, South Africa, North Africa)

Regional Overview

On the basis of geography, light sensor market can be segmented into seven key markets namely North America, Latin America, Western Europe, Eastern Europe, APAC, Japan, Middle East and Africa. Asia-Pacific is expected to dominate the light sensors market because of its larger population size and increasing demand for smartphone and other consumer electronics. Asia Pacific is expected to be followed by North America and Europe region.

Request For TOC:


Increasing demand for light sensors from verticals such as consumer electronics, automotive building automation, industrial manufacturing etc. supported by its increasing number of applications across the verticals is expected to drive the demand for light sensors. Among the verticals, consumer electronics is expected to dominate the market for light sensors supported by increasing demand for Asia-Pacific and North America region.

Competitive Landscape

Major players in the field of application delivery controllers include ams AG (Germany), Maxim Integrated (U.S.), Vishay Intertechnology (U.S.), ROHM Semiconductor (Japan), ELAN Microelectronics Corporation (Taiwan), Heptagon (Singapore) etc. Major mobile manufacturing companies such as Samsung are going into partnership with light sensor manufacturers so as to integrate both the technologies.

Heliospectra AB (HLSPY: OTCQB) | CFN Media Exclusive Video: See How a Grower Produces Consistent Top Quality MMJ

SEATTLE, WA–(Marketwired – Apr 26, 2017) – CFN Media Group („CFN Media”, CannabisFN”), the leading agency and digital media network dedicated to the North American cannabis industry, today announced the release of a three-part video series focused on the work of Ryan Aubin, founder of Central Maine Flower, a medical marijuana caregiver service located in Bangor, Maine. Ryan uses Heliospectra AB’s (OTCQB: HLSPY) powerful, energy-efficient LED broad-spectrum lighting solutions. Heliospectra is a leader in intelligent lighting technology for greenhouses and controlled plant growth environments. The company’s holistic and flexible lighting solutions consistently increase yields while producing crops that achieve quality appearance, superior nutritional or medicinal value, and longer shelf life.

„It’s important that your procedures are clean and your product comes out top notch every time because a variation in THC production or even the way it looks — if a bud doesn’t look consistent for that patient every time they come to buy it — you will lose them as a customer,” says Founder Ryan Aubin. „And for us, we’re only allowed to have a few patients at a time, so it’s very important to keep those people happy and provide them with what they’re looking for.”

„I’m seeing a lot more density in our flowers compared to a grower using high pressure sodium (HPS) lights,” says Ryan. „I’m seeing the actual amount of time it takes to trim these flowers greatly reduced because you’re harvesting less leaf from the bud area. With the Heliospectra lights, the quality and intensity is there, the full-spectrum intensity. And you can actually see the light start to penetrate through the canopy and all the way to the bottom of the floor.”

Please follow the link to view the videos:

Heliospectra AB was founded in 2006 and is the industry’s most proven intelligent lighting technology for greenhouse and controlled plant growth environments, with the vision to make commercial crop production more connected and resource-efficient. Growers and commercial producers across six continents use Heliospectra’s holistic and flexible solutions to consistently increase yields while producing crops that achieve quality appearance, superior nutritional or medicinal value and longer shelf life, harvest after harvest. Winner of multiple international awards and recognitions, Heliospectra has raised more than $32 million in capital to date.

Learn how to become a CFN Media client company, brand or entrepreneur:

Download the CFN Media iOS mobile app to access the world of cannabis from the palm of your hand:

Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone:

About CFN Media

CFN Media (CannabisFN), the leading creative agency and media network dedicated to legal cannabis, helps marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.

CFN launched in June of 2013 to initially serve the growing universe of publicly traded marijuana companies across North America. Today, CFN Media is also the digital media choice for the emerging brands in the space.

Copyright © 2017 Marketwired. All Rights Reserved

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

FMI Brings Report on Oilfield Chemical Market with Current Trends Analysis, 2016-2026

Valley Cottage, NY — (SBWIRE) — 04/26/2017 — The increasing population have augmented the energy requirements of the country. In order to cope with energy demands more Oil and Gas E&P initiatives are being taken to cover the household and industrial energy requirement. With the products of oil industries & Gas manufacturing process fuelling various different industries from chemical to cosmetic hence it is necessary to use ensure that only quality product with minimum wastage is available . In order to ensure easy extraction, production a rich and refined product we use oilfield chemicals. With the use of Oilfields chemicals ensure an increase in efficiency oilfield activities such as drilling, completion, production, cementing and enhanced oil recovery (EOR). The Specialty oilfield chemicals impart unique attributes and functionality to the crude product to enhance their recovery of hydrocarbons from the well. Various categories of specialty oilfield chemicals include corrosion inhibitors, emulsion breakers (demulsifiers), surfactants and advanced polymers. Emulsion breakers are used to separate oil and water from crude oil water emulsions and corrosion inhibitors are those chemicals that inhibit corrosion of mild steel equipments in any aqueous medium. Hence, such agent help in increasing the export value of the crude oil thus are essential for use of the Oil and Gas industry.

Oilfield Chemical Market: Drivers & Restraints

To meet the ever increasing demands of energy more Onshore and offshore exploration initiatives are being taken therefore driving the market for oilfield chemicals The increase drilling activity and use of technologies such as hydraulic fracturing and enhanced oil recovery (EOR) boost the demand of oilfield chemicals on global basis to ensure efficient oil and gas recovery. The development in the Oil and Gas industry will directly affect the oilfield chemical market. In order to get premium crude oil with high hydrocarbon content the usage of EOR chemicals is also increasing. These efforts will boost demand for EOR chemicals and of stimulation fluids. Crude oil price volatility could prove as a restrain to the market of Oilfield chemicals over the forecast period. With developing fields of unconventional energy sources the over dependence on hydrocarbons is decreasing and hence the research for environment friendly and biodegradable oilfield chemicals provide promising opportunities in the market for industry participants.

Request For Report Sample@

Oilfield Chemical Market: Segmentation

The Oilfield chemicals can be segmented on the basis of its function as:

Drilling Fluids
Water-Based Muds
Oil-Based Muds
Synthetic-Based Muds
Work over and Completion Fluids
Cementing Chemicals
Stimulation Chemicals

Oilfield Chemical are segmented on the basis of Enhanced Oil Recovery Chemicals as:

Alkali Surfactant Polymer Flooding
Low-Salinity Water Injection
Water Shut-Off Chemicals
Carbon Dioxide Flooding
Microbial IOR

Oilfield Chemical Market: Regional Outlook

The Middle East being one of the largest markets for crude oil applications such as oil-based power plants, petro refineries, and sludge oil treatment and with the discoveries of more fields in different regions will be one of the strongest and largest market for oilfield chemical and will project greatest growth potential over the forecast years. The growth potential for the regions of Russia will prove to be strong and positive reinforcement for the oilfield market. The shale gas production in U.S. is expected to provide a boost to the Oilfield chemical market.Growth in Latin America, particularly in Brazil and Venezuela, has been significant but could be influenced by the political instability. In Asia Pacific, the emerging economies of China and India are said to one of the most promising market for oilfield chemicals with increase in oil extraction activities.

Request For TOC@

Oilfield Chemical Market: Key players

Some of the key players in the Oilfield chemical market are Schlumberger, Stephan Company BASF SE, Dow Chemicals Co., The Lubrizol Corporation, Azko Nobel N.V.

OncBioMune Pharmaceuticals, Inc. (OBMP: OTCQB) | OncBioMune, AqVida Partner for Commercializing Cancer and Other Generic Drugs in Mexico

Companies Negotiating Joint Venture for Clinical Development of ProscaVax for Prostate Cancer in Europe

BATON ROUGE, LA–(Marketwired – April 26, 2017) – OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) („OncBioMune” or the „Company”), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, today announces an exclusive distribution and licensing agreement between OncBioMune and AqVida GmbH („AqVida”), a Germany-based FDF manufacturer specializing in the development, registration, manufacturing and distribution of generic pharmaceutical products, with an emphasis on the field of cancer therapy from their state-of-the-art facility in Dassow, Germany.

As agreed upon, AqVida is granting OncBioMune the rights to several oncology and other generic pharmaceuticals in their portfolio, including imatinib, docetaxel and azathioprine to name a few, for commercialization in the Mexican markets. AqVida has commericialized these products for sale in the European markets. AqVida will support OncBioMune’s efforts through providing all requisite documentation for seeking marketing approval in Mexico and manufacturing the products at their GMP-certified facility in Germany.

Additionally, OncBioMune and AqVida are conducting negotiations regarding expanding the exclusive licensing agreement to cover commercialization in the Mexican markets the complete AqVida portfolio of medicines, including several used for treating the most common types of cancer.

Furthermore, AqVida has expressed interest in being involved in the development of ProscaVax, OncBioMune’s novel therapeutic cancer vaccine currently undergoing clinical research as a new treatment for prostate cancer. The two companies are contemplating a joint venture in which AqVida would be integral in the clinical development of ProscaVax in Europe, including leading the initiation of clinical studies and manufacturing ProscaVax for use within the highly regulated E.U. market.

„This is another incredible step in our growth as we aim to build an international footprint and become a leading name in generic drugs in Mexico,” commented Dr. Jonathan Head, Chief Executive Officer at OncBioMune. „AqVida has a strong presence in Europe and in the oncology space, giving us another high quality partner with deep experience in bringing new drugs to market globally. The relationship with AqVida will allow us to commercialize the products at competitive prices, which we believe will result in capturing a meaningful market share across the board.”

„As successful as our generics are throughout Europe, there is a large, untapped market in Mexico for which OncBioMune is an ideal partner to capitalize with its extensive distribution network and experience with the regulatory pathway,” said Wolfgang Heinze, CEO at AqVida. „We further see many other synergies between our companies for leveraging resources to introduce our other generics to Mexico and Latin America and to develop ProscaVax for the vast European markets. Approximately 400,000 new cases of prostate cancer are diagnosed each year in Europe and over 92,000 lives are lost annually to the disease. Radical prostatectomy remains a leading therapy and we are of the opinion that a safe and effective new treatment would be warmly welcomed across the entire union. We’d like to be a part of developing such a therapy.”

Sign up for OncBioMune email alerts at:

About AqVida GmbH

AqVida is a German oncology FDF manufacturer that is fully dedicated and specialized in the development, registration, manufacturing and distribution of finished dosage forms mainly for the oncology sector. It has developed a portfolio of medicines for treating the most common types of cancer. AqVida’s expertise in generic oncology products has made the company a leading partner in the pharmaceutical industry. AqVida works alongside some of the leading names in the oncology sector. In co-operation with its partners, AqVida has achieved substantial development and growth with its oncology portfolio. AqVida is a pharmaceutical company with an impressive track record in fulfilling all client requirements from API sourcing through to EU market release for finished products. Teams of experts in development, regulatory affairs, patent issues and laboratory work bring skills and knowledge together to achieve optimum results for customers. AqVida complies with all German and EU legal requirements for the pharmaceutical industry and is GMP certified by the German Health Authorities. As a European organization, AqVida has the knowledge and resources to provide regulatory support to meet the requirements of the complex and highly regulated EU market.

About OncBioMune Pharmaceuticals, Inc.

OncBioMune Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a proprietary Vaccine Technology that is designed to stimulate the immune system to attack its own cancer while not hurting the patient. Our lead product, ProscaVax™ is scheduled to commence a Phase 2 clinical study in 2016. OncBioMune also has a portfolio of targeted therapies, some of which are biosimilars to blockbuster drugs. OncBioMune is headquartered in Baton Rouge, LA.

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor there be any sale of these securities in any jurisdiction in which such offer solicitation or sale are unlawful prior to registration or qualification under securities laws of any such jurisdiction.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause OncBioMune Pharmaceuticals’ actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. OncBioMune Pharmaceuticals has in some cases identified forward-looking statements by using words such as „anticipates,” „believes,” „hopes,” „estimates,” „looks,” „expects,” „plans,” „intends,” „goal,” „potential,” „may,” „suggest,” and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are OncBioMune Pharmaceuticals’ need for, and the availability of, substantial capital in the future to fund its operations and research and development; the fact that OncBioMune Pharmaceutical’s vaccines and therapeutics may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in OncBioMune Pharmaceutical’s filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. OncBioMune Pharmaceuticals undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.

Copyright © 2017 Marketwired. All Rights Reserved

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

FMI Features Report on Pour Point Depressants Market Forecast by End-Use Industry 2016-2026

Valley Cottage, NY — (SBWIRE) — 04/26/2017 — Pour Point Depressants (PPD) are polymers which lowers the temperature to suppress the precipitation of hydrocarbons present in oil. Pour Point Depressants are also known as paraffin inhibitors. Pour point depressants interlocks the waxy materials or paraffin by co-crystallization and modify the shape of crystals to increase the fluidity of oil or fluid. Good quality pour point depressants lowers the pour point up to 400C. However, polymethacrylates and alkylaromatic polymers lower the pour point up to 10-200C. The addition of pour point depressants improve the performance of fluid. Pour point depressants are used widely in oil and gas industry so as to enhance the flow characteristics, which helps in easy handling, transportation and storage of crude oil. Automotive industry is expected to contribute a major share in the global pour point depressants market. Moreover, revenue from the sales of pour point depressants across the globe is expected to increase at a moderate CAGR over the forecast period.

Pour Point Depressants Market: Drivers and Restraints

The competitive edge of pour point depressants over other alternatives with properties such as enhancing the fuel lubricity, reduced viscosity, and performance enhancement of flow of crude oil is expected to be the major demand driving factor for the growth of global pour depressants market. The growth of automobile industry is one of the major factors driving the growth of the global pour point depressant market. Moreover, the rising demand of engine oils, tractor fluids and power transmission fluids is in turn expected to fuel the overall growth of the global pour point depressant market. In addition, increasing refining capacity across the globe and rapid industrialization are some other driving factors boosting the growth of the global pour point depressant market.

Request For Report Sample@

Neat biodiesel with suitable modification is expected to be one of the restraining factors for the growth of global pour point depressant market. Moreover, nanoparticles can be an alternative to challenge the global pour point depressant market. The global economic crises, specifically in China is also expected to be a major threat for the growth of global pour point depressants market.

Pour Point Depressants Market: Segmentation

On the basis of chemistry, the global pour point depressant can be segmented into

Alkylaromatic polymers
Styrene esters
Oligomerized alkyl phenols
Phthalic acid esters
Copolymers of alpha- olefins

On the basis of end user application, the global pour point depressant market can be segmented into

Oil and gas industries
Marine industries
Lubricant industries
Automotive industry

Pour Point Depressants Market: Regional Outlook

On the basis of region the global pour point depressant market is segmented into North America, Latin America, Western Europe, Eastern Europe, Middle East and Africa, Asia Pacific Countries excluding Japan and Japan. Asia pacific is expected to contribute maximum share in terms of value to the revenue generated from the sales of pour point depressants globally. This region is expected to retain its dominance throughout the forecast period. China is estimated to be the fastest growing country in the global pour point depressants market. India and South Korea are also expected to contribute maximum share in the global pour point depressants market over the forecast period.

Request For TOC@

Pour Point Depressants Market: Major key players

Some of the major players identified in the global pour point depressants market are:

Global Partners LP
Chevron Phillips Chemical Company
Croda International Plc
Messina Chemicals
Evonik Industries AG
Afton Chemical Corporation
Royal Dutch Shell plc
Clariant Corporation
The Lubrizol Corporation

FMI Estimates Decorative Car Accessories Market to Enhance at Steady Growth Rate

Valley Cottage, NY — (SBWIRE) — 04/26/2017 — The decorative car accessories market has become quite established due to increasing popularity of car customisation among consumers. Focus on enhancing car aesthetics and improving comfort are the key factors that have led to renewed interest in decorative car accessories. Over the years, the decorative car accessories market has grown in terms of product range & application types.

Decorative Car Accessories Market Dynamics

Demand for decorative car accessories is higher in the aftermarket segment than the original equipment manufacturer (OEM) segment. The aftermarket segment is less expensive and offers a more diverse range of customisation in terms of design & material types. Franchise-based sales channels & regional dealers are the prominent players in both value chain and supply chain. The supply chain consists of conventional physical sales channel as well as online sales. Phone-based application sales is a new channel which has grown robustly in recent times.

Many dealers are creating their own brand / range of accessories in association with the parent OEM, thereby adopting a strategic alliance. Marketing and promotion via social platforms, trade fairs & exhibitions, motor racing events, seminars, and print & electronic media are thoroughly used for product positioning & consumer awareness.

Request For Report Sample@

Decorative Car Accessories Market Segmentation

The decorative car accessories market constitutes the nature of accessory and its range of product types involved — these products can be classified as:

Pedals & Car Mats
Racing Seats
Steering Wheel & Seat Covers
Interior Trims
Door Sills
Racks & Carriers
Spoilers & Wings
Mud & Splash Guards
Door Skins
Light Bars
Exhausts & Mufflers
Air Intake Systems
Decals & Stickers

The decorative car accessories market can be segregated on basis of car type as: compact, sedan, executive, SUV/MUV, luxury, and premium.

Regional bifurcation of the market for decorative car accessories are as follows:

North America, Latin America, Western Europe, Eastern Europe, Asia Pacific exc. Japan (APEJ), Japan, and Middle East & Africa (MEA).

Request For TOC@

Decorative Car Accessories Market: Regional Outlook

Geographically, the decorative car accessories industry is present across all major regions which include North America, Western & Eastern Europe, Asia-Pacific region, Japan, and Middle East & Africa. The North American decorative car accessories market is the largest contributor with highest consumer base. The market will witness healthy growth rates owing to stable automotive sales. The market would be volume driven across all regions and car types. Value additions by suppliers and a strong sales channel would be key requisites of the market.

Decorative Car Accessories Market Players

The major players including manufacturers & suppliers identified across the global value chain are Delphi Automotive, Robert Bosch GmbH, Continental AG, Denso Corporation, Magna International, Aisin Seiki Co. Ltd., Tenneco Inc., and Federal Mogul Corp. Amongst others there are prime regional manufacturers, such as 3d Carbon Automotive Corp., Carroll Shelby International Inc., Roush Performance Products Inc., Steeda Autosports, Classic Design Concepts, JC Whitney, Driven By Style LLC, HKS Co. Ltd., Sparco Motor Sports Inc., and Injen Technology.

MPEG LAがCRISPR-Cas9特許の一括ライセンスでのプール化を呼び掛け

デンバー–(BUSINESS WIRE)–(ビジネスワイヤ) — ライセンシングの世界的リーダー企業MPEG LAは本日、CRISPR-Cas9特許の保有者に世界的なCRISPR-Cas9共同ライセンシングプラットフォーム創設への参加を呼び掛けました。本プラットフォームは、これら保有者の画期的技術への広範なアクセスを実現するためのものです。

MPEG LA社長兼最高経営責任者(CEO)のラリー・ホーンは、次のように述べています。「CRISPRの基礎的な特許権を非独占的でコスト効率と透明性を備えたシングルライセンスの下でプールすることで、この市場でCRISPRの導入を加速・拡大させる新規製品/治療薬の創出に傾注できるようになります。ちょうどMPEG LAの先駆的な努力でライセンシング間接費の管理と訴訟リスクの低減に取り組み、消費者向け電子機器産業でデジタルビデオの成功を確かなものとすることに貢献したように、CRISPR-Cas9共同ライセンシングプラットフォームは同じ成果をヘルスケア、その他のバイオテクノロジー産業ではるかに大きな影響力でもって達成することができます。」

MPEG LAのバイオテクノロジーライセンシング担当エグゼクティブディレクターであるクリスティン・ニューマンは、次のように述べています。「さらに、基礎的特許およびその他の特許の保有者は、本プールの合理的なロイヤルティーを公平に共有することで各自の発明が報われるとともに、さらなる開発意欲をかき立てられることになります。独立管理型プールは自発的で市場本位のソリューションとしてアクセスとインセンティブのバランスを取るものであり、人類に貢献するCRISPRの潜在力すべてを解き放つ形で、市場と公共の利益に対処する上での最高の希望をもたらします。」

共同ライセンシングプラットフォームの創設に最初から参加するチャンスを得たいと思うCRISPR-Cas9特許保有者に対して、MPEG LAはをご覧いただくことをお勧めします。特許提出についての条件と手順書、資格を含め、詳細情報を入手いただけます。1件以上の対象特許をライセンス開発プロセスに進める必要があり、提出者にとっての経費負担なしでMPEG LAが資格について決定します。関係者は2017年6月30日までに最初の特許を提出するようお願いします。特許の提出は今後も受け付け、本共同ライセンスが市場の利益になるようできるだけ多くの関連知的財産を含むようにしますが、同日までに特許を提出する方および有資格と考える方はその他の有資格の特許権保有者と初期会合に参加して、CRISPR-Cas9共同ライセンシングプラットフォームの基盤となり得る共同条件の可能性を検討していただくように呼び掛けます。有資格の特許保有者が本共同ライセンシングプラットフォームへの参加を決定する時まで、守秘義務を除き、今後の会合への参加など、義務や誓約の必要はありません。


MPEG LAは、規格とその他の技術プラットフォームのライセンスをワンストップで提供する世界的大手です。1990年代より、現代の特許プールを先駆的に形成し、史上最高の普及度を誇る消費者向け電子機器の規格を生み出す上で貢献してきました。MPEG LAは、さまざまな技術を対象に1万4000件以上の特許から構成されたライセンシングプログラムを84カ国で運営してきました。特許保有者は約230、ライセンシーは6000を超えます。ユーザーが選択した技術の導入支援に当たるMPEG LAは、基本的な知的財産へのアクセスと運用の自由を提供し、訴訟のリスクを低減し、事業計画のプロセスに予測可能性をもたらしています。その代わりに、発明家、研究機関、その他の技術所有者が自身の資産を収益化し、世界市場における導入を加速化すると同時に、ライセンシング費用を大幅に削減できるようにしています。消費者向け電子機器に加え、MPEG LAは先進的なリチウムイオン電池、その他の遺伝子編集を対象とする特許プールを開発しており、分子診断製品とオリゴヌクレオチド治療薬のためのライセンシングベンチャーを構想しています。詳細情報についてはwww.mpegla.comをご覧ください。